News & Events
-
3rd Annual RAS-Targeted Drug Development Summit
When: Sep. 21st, 2021 to Sep. 23rd, 2021
Anima Biotech has been invited to participate on an expert panel during the 3rd Annual RAS-Targeted Drug Development meeting. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will participate as an expert on a panel titled, “Exploring Chemistry Between Mutations: How to Exploit Mutations for Selective Targeting.” This year’s meeting will mark the largest summit in the RAS series to date. After decades of R&D efforts into targeted KRAS therapies, this year’s summit will serve as an all-inclusive program addressing emerging strategies to target all RAS mutations, robust and effective combination strategies and shining a spotlight onto optimized clinical translation and clinical trials in progress.
-
Undruggable Leaders Forum
When: Sep. 15th, 2021 to Sep. 16th, 2021
Anima Biotech has been invited to participate in the 2021 Undruggable Leaders Forum. Yochi Slonim, CEO, will serve as an expert during a fireside chat alongside Beth Shafer, Head of Neuroscience, Drug Discovery Sciences and Externalization Business Development at Takeda. This session will explore Anima-Takeda collaboration for the discovery and development of mRNA translation modulators for Neurological diseases. The Undruggable Leaders Forum was established with the mission of uniting key experts to discuss the latest scientific developments and clinical breakthroughs in diseases currently deemed “undruggable.”
-
5th IPF Summit 2021
When: Aug. 25th, 2021 to Aug. 27th, 2021
Anima Biotech has been invited to give a presentation at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Multiple mechanisms for Collagen mRNA translation regulation in IPF: from mRNA processing to mRNA translation.” The 5th IPF Summit will be an opportunity to learn from industry experts and gain the knowledge needed to tackle tough translational and clinical hurdles to ultimately develop more reliable, effective and disease modifying IPF drugs. Speakers will present innovative research and provide updates on state-of-the-art science to make meaningful impact on the lives of the 3 million patients suffering with IPF worldwide.
-
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles
Anima to an undisclosed milestone payment.“Since announcing our partnership with Anima back in March, our research collaboration has kicked off to a success with the achievement of this first milestone,” said Ceri Davies Head, Neuroscience Drug Discovery Unit at Takeda.
“We are delighted to announce this successful milestone in our strategic collaboration with Takeda which demonstrates the advantage of our approach with small molecule mRNA drugs. We are highly motivated to keep advancing the Huntington’s Disease program and the overall collaboration” said Yochi Slonim, Anima’s co-founder & CEO.
-
UBS Innovation Series: The Next Wave in Neurodegeneration
When: Jun. 3rd, 2021
Anima Biotech has been invited to participate in a presentation at the UBS Innovation Series: The Next Wave in Neurodegeneration. The presentation by Yochi Slonim, CEO, will feature Anima Biotech’s proprietary technology platform and its use in developing mRNA translation modulators for neurodegenerative disorders, such as Alzheimer’s disease. The virtual conference will shed light on the latest advancements in neurodegeneration.
-
Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs
When: May. 18th, 2021 to May. 19th, 2021
Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting mRNA Translation in a Tissue Selective and Disease-Specific Manner with Small Molecules.” Additionally, Dr. Alroy will serve as an expert on a panel during the virtual meeting. The conference was established to highlight some of the innovative approaches being pursued to find new small molecule drugs for targeting RNA for therapeutics intervention.
-
Sachs 4th Annual Neuroscience Innovation Forum
When: Apr. 28th, 2021 to Apr. 30th, 2021
Anima Biotech has been invited to participate in a live panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Pharma Partnering and M&A: An Update on DealMaking Panel.” The virtual conference will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by leading industry experts. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech and medtech companies.
-
1st Interstitial Lung Disease Drug Development Summit
When: Apr. 27th, 2021 to Apr. 29th, 2021
Anima Biotech has been invited to give a presentation at the 1st Interstitial Lung Disease Drug Development Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting Collagen I mRNA Translation in a Tissue Selective Manner with Small Molecules.” The 1st ILD Summit is a new and groundbreaking conference dedicated to helping industry drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. During the virtual conference, leading experts will share critical insights to help attendees define, understand and develop clinically effective antifibrotic therapies against the progressive fibrosing ILD phenotype Scleroderma, Sjogren’s Syndrome, Sarcoidosis, Hypersensitivity Pneumonitis and more.
-
Undruggable Leaders Forum Europe
When: Apr. 13th, 2021 to Apr. 14th, 2021
Anima Biotech has been invited to present a corporate overview at the Undruggable Leaders Forum Europe. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development, will present a corporate overview during a session titled, “Novel Approach for the Discovery of Small Molecules that Selectively Control mRNA Translation as a New Strategy Against Undruggable Proteins.”
The Undruggable Leaders Forum Europe will provide a forum for world leaders to discuss key challenges uniting all modalities against intractable targets, in addition to the latest developments in the field. Attendees will be provided an opportunity to explore the latest research and discover how these challenges are being met.
-
Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases
When: Mar. 18th, 2021
Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced that the company has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop a new class of medicines for genetically-defined neurological diseases.
Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize.
The preclinical research collaboration will initially include Anima’s early Huntington’s Disease program against the HTT target, selectively inhibiting the mutated protein with small molecules and two additional targets named by Takeda, related to neurological diseases. Takeda will pay Anima up to approximately $120 million in upfront and preclinical research milestone payments and up to $1.1 billion in clinical and commercial milestones, assuming success of the three programs. Anima is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Takeda has a time limited option to expand the collaboration with up to three additional targets subject to additional payments to Anima of up to $1.2 billion and tiered royalties, assuming success of these programs.
“Anima Biotech’s expertise in understanding the complex regulatory mechanisms of protein expression in the central nervous system makes them an ideal partner to explore this novel area of drug discovery,” said Ceri Davies, Head, Neuroscience Drug Discovery Unit at Takeda. “By combining Anima’s platform with our strength in translational medicine and clinical development, we aim to develop medicines that deliver greater benefits to patients with genetically-defined neurological diseases where there are non-existent or ineffective treatment options.”
“Partnering is a core strategy of Anima and our model is to build collaborations that maximize the probability of success by combining our discovery platform and expertise in translation control biology with the scientific, clinical and commercial capabilities of our partners,” said Yochi Slonim, Anima’s co-founder & CEO. “Takeda‘s leadership and depth of scientific expertise in the CNS area is ideally suited for our second Pharma partnership in Neuroscience and further validates our leadership in mRNA translation control. We are looking forward to working together with Takeda in a true collaboration model.”